BioNexus Gene Lab (BGLC) Assets (2018 - 2026)

BioNexus Gene Lab has disclosed Assets across 9 years of filings, most recently posting $8.7 million for Q2 2026.

• In Q2 2026, Assets fell 7.37% year-over-year to $8.7 million; the TTM figure through Jun 2026 stood at $8.7 million (down 7.37% YoY), while the FY2025 annual figure was $9.3 million, down 11.32% from the prior year.
• Assets came in at $8.7 million for Q2 2026 at BioNexus Gene Lab, down from $9.0 million in the prior quarter.
• In the past five years, Assets ranged from a high of $11.5 million in Q3 2023 to a low of $7.6 million in Q3 2025.
• Average Assets over 5 years is $9.5 million, with a median of $9.2 million recorded in 2022.
• Year-over-year, Assets surged 47.03% in 2023 and tumbled 30.68% in 2025.
• Over 5 years, Assets stood at $8.7 million in 2022, then jumped by 30.43% to $11.4 million in 2023, then dropped by 8.47% to $10.4 million in 2024, then dropped by 11.32% to $9.3 million in 2025, then dropped by 5.69% to $8.7 million in 2026.
• Per Business Quant data, the three most recent Assets figures were $8.7 million in Q2 2026, $9.0 million in Q1 2026, and $9.3 million in Q4 2025.